Abstract
Evidence supports the idea that substantial benefits may derive from treatments that increase high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein (apo) A-I, HDL2 (or 2b) or the size of HDL particles with, or without, apo A-II. HDL3 appears to be neutral in terms of coronary artery disease risk, and apo A-II appears to be adverse. Because HDL particles serve as antioxidants in vitro, the hypothesis that low HDL-C reflects an antioxidant deficiency state appears tenable. Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adult
-
Aged
-
Antioxidants / adverse effects
-
Antioxidants / therapeutic use*
-
Cholesterol, HDL / blood*
-
Coronary Angiography
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / drug therapy*
-
Coronary Disease / blood
-
Coronary Disease / drug therapy*
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Hypolipidemic Agents / adverse effects
-
Hypolipidemic Agents / therapeutic use*
-
Lovastatin / adverse effects
-
Lovastatin / therapeutic use
-
Male
-
Middle Aged
-
Myocardial Revascularization*
-
Niacin / adverse effects
-
Niacin / therapeutic use
-
Simvastatin / adverse effects
-
Simvastatin / therapeutic use
-
Treatment Outcome
-
Vitamins / adverse effects
-
Vitamins / therapeutic use*
Substances
-
Antioxidants
-
Cholesterol, HDL
-
Hypolipidemic Agents
-
Vitamins
-
Niacin
-
Lovastatin
-
Simvastatin